Literature DB >> 7590676

Defective corticotropin-releasing hormone mediated neuroendocrine and behavioral responses in cholestatic rats: implications for cholestatic liver disease-related sickness behaviors.

M G Swain1, M Maric.   

Abstract

Nonspecific systemic complaints are commonly encountered in patients with cholestatic liver diseases. However, the cause of these symptoms is poorly understood. Because corticotropin-releasing hormone (CRH) has been implicated as a mediator of sickness-related systemic symptoms, we examined CRH-mediated neuroendocrine and behavioral responses in rats with cholestasis due to bile duct resection (BDR) or sham resected (sham) controls. BDR and sham rats were placed individually in an open field apparatus, and the number of inner and outer squares entered, as well as the number of fecal boli produced, counted over a 5-minute period. Fecal boli production and inner squares entered are dependent on central CRH release. BDR and sham rats entered the same number of outer squares; however, BDR rats entered significantly fewer inner squares and produced fewer fecal boli than did sham rats, suggesting defective central CRH release in BDR rats. Immediately after exposure to the open field, rats were killed and blood adrenocorticotropic hormone (ACTH) levels measured. ACTH release is dependent on central CRH release. BDR rats demonstrated significantly lower plasma ACTH levels after exposure to an open field than did sham animals. To further explore the central CRH defect in BDR rats, hypothalamic CRH contents were determined in BDR and sham rats with and without exposure to restraint stress. BDR rats had significantly lower basal hypothalamic CRH levels than sham animals, and CRH levels did not further decrease in BDR rats with restraint stress (as normally occurs). These results are consistent with defective CRH-mediated responses in cholestatic rats.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7590676

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  15 in total

Review 1.  Fatigue in cholestatic liver disease--a perplexing symptom.

Authors:  D Kumar; R K Tandon
Journal:  Postgrad Med J       Date:  2002-07       Impact factor: 2.401

Review 2.  Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy.

Authors:  Thomas Pusl; Ulrich Beuers
Journal:  Clin Rev Allergy Immunol       Date:  2005-04       Impact factor: 8.667

3.  Muscle fatigue in women with primary biliary cirrhosis: Spectral analysis of surface electromyography.

Authors:  Maria Rosa Biagini; Alessandro Tozzi; Antonello Grippo; Andrea Galli; Stefano Milani; Aldo Amantini
Journal:  World J Gastroenterol       Date:  2006-08-28       Impact factor: 5.742

4.  Effect of ondansetron, a 5-HT3 receptor antagonist, on fatigue in chronic hepatitis C: a randomised, double blind, placebo controlled study.

Authors:  T Piche; G Vanbiervliet; F Cherikh; Z Antoun; P M Huet; E Gelsi; J-F Demarquay; F-X Caroli-Bosc; S Benzaken; M-C Rigault; C Renou; P Rampal; A Tran
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

5.  Suppression of the HPA Axis During Cholestasis Can Be Attributed to Hypothalamic Bile Acid Signaling.

Authors:  Matthew McMillin; Gabriel Frampton; Matthew Quinn; Ali Divan; Stephanie Grant; Nisha Patel; Karen Newell-Rogers; Sharon DeMorrow
Journal:  Mol Endocrinol       Date:  2015-10-02

6.  Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double-blind controlled trial.

Authors:  Jayant A Talwalkar; Jessica J Donlinger; Andrea A Gossard; Jill C Keach; Roberta A Jorgensen; Janice C Petz; Keith D Lindor
Journal:  Dig Dis Sci       Date:  2006-10-20       Impact factor: 3.199

7.  Fatigue is associated with high circulating leptin levels in chronic hepatitis C.

Authors:  T Piche; E Gelsi; S M Schneider; X Hébuterne; J Giudicelli; B Ferrua; C Laffont; S Benzaken; P Hastier; M L Montoya; F Longo; P Rampal; A Tran
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

8.  Fatigue in primary biliary cirrhosis.

Authors:  K Cauch-Dudek; S Abbey; D E Stewart; E J Heathcote
Journal:  Gut       Date:  1998-11       Impact factor: 23.059

Review 9.  Pathophysiology of cancer-related fatigue.

Authors:  Xin Shelley Wang
Journal:  Clin J Oncol Nurs       Date:  2008-10       Impact factor: 1.027

10.  Fatigue in chronic cholestasis.

Authors:  P Milkiewicz; E J Heathcote
Journal:  Gut       Date:  2004-04       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.